Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Third-quarter events to watch for large drug makers
Biogen’s aducanumab filing is keenly awaited, as are clinical data from Sanofi, Bristol Myers Squibb, Lilly and others.
The bladder cancer pendulum swings towards Bavencio
As Merck & Co’s Keynote-361 study fails, attention turns to Bavencio’s Asco late-breaker and the potential of Padcev.
Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Asco 2020 – after Tecentriq’s liver win the spotlight falls on Merck and Astra
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Asco 2020 – J&J sees multiple myeloma responses deepen
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
